ScripSumitomo Dainippon Pharma Co. Ltd. (SDP) and Japanese bioventure SanBio Co. Ltd. have decided to end their alliance for the joint development of SB623, a mesenchymal stem cell (MSC)-based therapy f
ScripFor years companies hoping to enter Japan complained of non-tariff trade barriers and a distribution system they viewed as nontransparent, inefficient, and saddled with high costs when compared to oth
ScripTOKYO – Mylan NV is the third-largest generics firm in the world, but it has lagged behind domestic competition in Japan despite an extensive portfolio. Meanwhile, Pfizer Inc. has been eager t